Maze Therapeutics (MAZE) Capital Expenditures (2024 - 2026)
Maze Therapeutics' (MAZE) quarterly Capital Expenditures came in at $6000.0 in Q1 2026, down 97.99% year-on-year from $299000.0 in Q1 2025, and up 100.79% quarter-over-quarter from -$755000.0 in Q4 2025.
Maze Therapeutics (MAZE) Capital Expenditures (2024 - 2026) Analysis & Trends
Maze Therapeutics has disclosed Capital Expenditures across 3 years of filings, most recently posting $6000.0 for Q1 2026.
- Capital Expenditures for Q1 2026 came in at $6000.0, down 97.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$288000.0 (down 120.59% YoY), and the FY2025 annual result was $5000.0, down 99.56% from the prior year.
- Capital Expenditures came in at $6000.0 for Q1 2026 at Maze Therapeutics, up from -$755000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $605000.0 in Q4 2024 to a low of -$755000.0 in Q4 2025.
- The 3-year median for Capital Expenditures is $103000.0 (2024), against an average of $128666.7.
- Peak annual rise in Capital Expenditures reached 536.17% in 2025, while the deepest fall reached 224.79% in 2025.
- Maze Therapeutics' Capital Expenditures stood at $605000.0 in 2024, then sank by 224.79% to -$755000.0 in 2025, then jumped by 100.79% to $6000.0 in 2026.
- The last three Capital Expenditures figures came in at $6000.0 (Q1 2026), -$755000.0 (Q4 2025), and $68000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -63,220.27 |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | -755,000.00 |
| Dec 31, 2025 | -755,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Dec 31, 2024 | 605,000.00 |
| Dec 31, 2024 | 605,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Mar 31, 2024 | 47,000.00 |
| Mar 31, 2024 | 47,000.00 |